Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma

被引：0
|
作者：
Bai, Xue
Li, Mei
Chen, Yu
Si, Lu
Chen, Jing
Pu, Xingxiang
Cheng, Ying
Zou, Zhengyun
Zhao, Shiwei
Li, Tao
Cai, Shengli
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[2] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[3] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China
[5] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Med Sch, Changsha, Peoples R China
[6] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[7] Nanjing Univ, Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China
[8] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[9] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9541
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PHASE I STUDY OF INTRATUMORAL NBTXR3 IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH ADVANCED CANCERS
    Shen, Colette
    Frakes, Jessica
    Niu, Jiaxin
    Weiss, Jared
    Caudell, Jimmy
    Jameson, Katherine
    Said, Patricia
    Seiwert, Tanguy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A249 - A249
  • [42] A PHASE 1 STUDY OF SERPLULIMAB (A NOVEL ANTI-PD-1 ANTIBODY) IN COMBINATION WITH HLX04 (AN ANTI-VEGF ANTIBODY) IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Guo, Y.
    Li, J.
    Li, Q.
    Xue, J.
    Xue, L.
    Ge, X.
    Lin, F.
    Zhao, W.
    Tang, W.
    Peng, D.
    Wang, Q.
    Zhu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S29 - S30
  • [43] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
  • [44] A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors
    Tolcher, Anthony
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony
    Vallaster, Markus P.
    Wang, Bushi
    Hyman, David
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [45] A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: Biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort
    Bendell, Johanna
    Ulahannan, Susanna V.
    Chu, Quincy
    Patel, Manish
    George, Ben
    Auguste, Aurelie
    Leo-Kress, Theresia
    Stadermann, Kai Bernd
    Kraemer, Nicole
    Elgadi, Mabrouk
    Johnson, Melissa
    CANCER RESEARCH, 2020, 80 (16)
  • [46] Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.
    Oh, Do-Youn
    Park, John J.
    Lee, Keun Wook
    Kim, Seung Tae
    Sriuranpong, Virote
    Rha, Sun Young
    Yoo, Changhoon
    Keam, Bhumsuk
    Sabanathan, Dhanusha
    Kim, Se Hyun
    Park, Joon Oh
    Parinyanitikul, Napa
    Kim, Min Hwan
    Kim, Kyu-Pyo
    Kim, Myungsuk
    Yoon, Jaebong
    Lee, Han Seung
    Ock, Chan-Young
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Phase 2 study of HDAC inhibitor tucidinostat in combination with anti-PD-1 antibody in patients with locally advanced or metastatic urothelial carcinoma
    Liu, Zhuowei
    Jiang, Lijuan
    Li, Xiangdong
    Ye, Yunlin
    Wu, Zhiming
    An, Xin
    Shi, Yanxia
    Yao, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study.
    Sheng, Xinan
    Chen, Haige
    Yao, Xin
    Hu, Yi
    Yao, Xudong
    Liu, Ziling
    Zhou, Fangjian
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Liberty-201: Maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC)
    Lenz, Heinz-Josef
    Yuan, Ying
    Li, Vivian
    Zhang, Juan
    Jamal, Lubna
    Lin, Xiao
    Zhu, Fuxiang
    Strickler, John H.
    CANCER RESEARCH, 2024, 84 (07)
  • [50] Initial Efficacy of Anti-Lymphocyte Activation Gene-3 (Anti-LAG-3; BMS-986016) in Combination with Nivolumab in Patients with Melanoma WHO Progressed During Prior Anti-PD-1/PD-L1 Therapy
    Ascierto, Paulo A.
    Melero, Ignacio
    Bhatia, Shailender
    Bono, Petri
    Sanborn, Rachel E.
    Lipson, Evan J.
    Callahan, Margaret K.
    Gajewski, Thomas
    Gomez-Roca, Carlos A.
    Hodi, F. Stephen
    Curigliano, Giuseppe
    Nyakas, Marta
    Preusser, Matthias
    Koguchi, Yoshinobu
    Maurer, Matthew
    Harbison, Christopher
    Mitra, Priyam
    Suryawanshi, Satyendra
    Munoz-Couselo, Eva
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 114 - 114
12345